Prevalencia de psoriasis secundaria a agentes biológicos en pacientes con artritis reumatoidea

Los objetivos del estudio fueron determinar la prevalencia de psoriasis en pacientes con Artritis Reumatoidea (AR) tratados con Agentes Biologicos (AB) y analizar sus caracteristicas clinicas en una poblacion de Tucuman.Se incluyeron 284 pacientes con AR. Ciento cuarenta y ocho en tratamiento con AB y 136 pacientes en tratamiento con Drogas Modificadoras de AR (DMAR), seleccionados por muestreo aleatorio simple. De los 284 pacientes evaluados, 242 (85%) fueron de sexo femenino, edad media de 56,4 anos ± 13,4, la edad media al diagnostico de AR fue de 42,3 anos ± 16,7 con un tiempo de evolucion de la enfermedad de 11,9 anos ± 8,5. Doscientos cuarenta y un pacientes (85%) fueron seropositivos para Factor Reumatoideo (FR). Ciento treinta y seis (48%) fueron tratados con DMAR y 148 (52%) con AB. Al comparar ambos grupos, no hubo diferencias significativas entre edad media, edad media al diagnostico de AR y presencia de factor reumatoideo. Cinco de los 148 pacientes en tratamiento biologico desarrollaron psoriasis. La prevalencia de psoriasis cutanea fue 3,4% (IC 95% 1,1-7,7). La mayoria de los casos se presentaron como psoriasis gutata. La duracion media del tratamiento hasta la aparicion de psoriasis fue de 31,6 meses (DS 26,8). Un paciente teniaantecedentes familiares de psoriasis. Ningun paciente del grupo DMAR desarrollo psoriasis (p The objectives of this study were to determine the prevalence of psoriasis in patients with rheumatoid arthritis (RA) who were treated with biological agents (BA) and analize its clinical features in apopulation of Tucuman. We included 284 patients with RA. One hundred and forty-eight patients received treated with AB and 136 patients were treated with disease modifying anti-rheumatic drugs (DMARD), and they were selected by simple random sampling. Of the 284 patients evaluated, 242 (85%) were female, mean age was 56.4 ± 13.4 years, mean age at diagnosis of RA was 42.3 ± 16.7 years with a mean time of disease progression of 11.9 ± 8.5 years. Two hundred and fourty-one patients (85%) were seropositive for rheumatoid factor. One hundred thirty-six patients (48%) were treated with DMARD and 148 (52%) received BA. When we compared both groups, there was no significant difference between mean age, age at diagnosis of RA and presence of rheumatoid factor.Five of 148 patients developed psoriasis in the BA group, after receiving the first BA. The prevalence of cutaneous psoriasis was 3.4% (95% CI 1.1-7.7). Most cases were presented as gutata psoriasis. The average duration of treatment to onset of psoriasis was31.6 months (SD 26.8). One patient had a family history of psoriasis. In the group with DMARD, neither patient developed psoriasis (p